Model: Anti-tumor efficacy
Anti-tumor efficacy models evaluate the therapeutic efficacy of a specific therapy using human xenograft or murine syngeneic animal models. These models can be used to advance preclinical drug development efforts. For example, a murine model of subcutaneous colorectal adenocarcinoma (CT26) was used to assess the impact of checkpoint blockade by anti-mPD-1, anti-mPD-L1 or anti-mCTLA-4 on established disease. These regimens were moderately responsive, enabling these data to inform downstream rational combination strategies with these agents.